Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

NCT00333411 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: BIRT 2584 XX
DRUG: Placebo

Sponsor

Boehringer Ingelheim